Last reviewed · How we verify
Experimental: Vehicle ophthalmic solution
A vehicle ophthalmic solution formulation designed to deliver therapeutic agents to the eye while maintaining ocular surface stability and drug bioavailability.
A vehicle ophthalmic solution formulation designed to deliver therapeutic agents to the eye while maintaining ocular surface stability and drug bioavailability. Used for Ophthalmic indication (specific indication not disclosed for this vehicle formulation).
At a glance
| Generic name | Experimental: Vehicle ophthalmic solution |
|---|---|
| Sponsor | Bausch & Lomb Incorporated |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Vehicle ophthalmic solutions serve as inert or minimally active carrier formulations that optimize drug delivery to ocular tissues. They typically contain buffering agents, osmolarity adjusters, and preservatives to maintain corneal integrity and enhance penetration of active pharmaceutical ingredients. The specific mechanism depends on the active agent being delivered, which is not specified for this experimental formulation.
Approved indications
- Ophthalmic indication (specific indication not disclosed for this vehicle formulation)
Common side effects
- Ocular irritation
- Conjunctival hyperemia
- Transient vision blurring
Key clinical trials
- An Investigation of FID 123320 for the Reduction of Ocular Redness in Pediatric and Adult Populations (PHASE3)
- Next Generation Rocklatan (PHASE2)
- A Double-Masked Comparison of FID 123320 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness (PHASE3)
- A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops (PHASE3)
- Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis (PHASE3)
- Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients (PHASE2)
- Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients (PHASE2)
- Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: